Qiagen N.V. (QGEN) — SEC Filings

Q: What are the key financial highlights for Qiagen N.V.?

Key financial highlights for Qiagen N.V. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Qiagen N.V.?

Key executives at Qiagen N.V. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Qiagen N.V. stock?

Risk factors for Qiagen N.V. (QGEN) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Qiagen N.V.?

Forward-looking statements and predictions from Qiagen N.V. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Qiagen N.V.. Recent 6-K filing on Dec 22, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Qiagen N.V. on SEC EDGAR

Overview

Qiagen N.V. (QGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Sep 2, 2025: QIAGEN N.V. filed a Form 6-K on September 2, 2025, for the quarterly period ended August 31, 2025. The filing is a report of a foreign private issuer and includes information on "Other Information," "Signatures," and an "Exhibit Index." QIAGEN N.V. is incorporated in the Netherlands and its fiscal y

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 5 bullish, 24 neutral. The dominant filing sentiment for Qiagen N.V. is neutral.

Filing Type Overview

Qiagen N.V. (QGEN) has filed 22 6-K, 2 20-F, 3 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (29)

6-K Filing — 6-K · Dec 22, 2025
6-K Filing — 6-K · Nov 6, 2025
QIAGEN N.V. Files Q3 2025 Report (6-K) — 6-K · Sep 2, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K on September 2, 2025, for the quarterly period ended August 31, 2025. The filing is a report of a foreign private issuer and includ
QIAGEN N.V. Files Q2 2025 6-K Report — 6-K · Aug 21, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K for the quarterly period ended June 30, 2025. The filing, submitted on August 21, 2025, is a report of a foreign private issuer. Th
QIAGEN N.V. Files Q2 2025 6-K Report — 6-K · Aug 7, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K on August 7, 2025, reporting on its quarterly period ended June 30, 2025. The filing is a report of a foreign private issuer and in
QIAGEN Appoints Stephen H. Rusckowski as Chairman — 6-K · Jun 30, 2025 Risk: low
QIAGEN N.V. announced on June 26, 2025, that its Supervisory Board has elected Stephen H. Rusckowski as Chairman. This decision follows the company's Annual Gen
QIAGEN N.V. Files Q1 2025 6-K Report — 6-K · May 13, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2025. The report is for a foreign private issuer and includes information on other matters
QIAGEN N.V. Files Q1 2025 6-K Report — 6-K · May 9, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2025. This report is for a foreign private issuer and includes information under 'Other In
QIAGEN Raises 2025 EPS Outlook on Strong Q1 — 6-K · Apr 9, 2025 Risk: low
QIAGEN N.V. announced preliminary Q1 2025 results on April 6, 2025, and raised its full-year 2025 adjusted earnings per share (EPS) outlook. The company provide
QIAGEN N.V. Files 2024 Annual Report — 20-F · Mar 31, 2025 Risk: low
QIAGEN N.V. filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial performance and business opera
QIAGEN N.V. Files 6-K for Q4 2024 Period — 6-K · Feb 7, 2025 Risk: low
QIAGEN N.V. filed a Form 6-K on February 7, 2025, reporting on its quarterly period ended December 31, 2024. The filing includes information about the company's
QIAGEN Completes Synthetic Share Repurchase Plan — 6-K · Jan 16, 2025 Risk: low
On January 16, 2025, QIAGEN N.V. announced the completion of a synthetic share repurchase plan. This plan involves a direct capital repayment combined with a re
QIAGEN to Return $300M to Shareholders via Synthetic Repurchase — 6-K · Jan 13, 2025 Risk: low
On January 12, 2025, QIAGEN N.V. announced plans to return approximately $300 million to its shareholders. This will be achieved through a synthetic share repur
QIAGEN N.V. Reports Change in Certifying Accountant — 6-K · Nov 8, 2024 Risk: low
QIAGEN N.V. filed a Form 6-K on November 8, 2024, reporting changes related to its certifying accountant for the period ending October 31, 2024. The filing indi
SC 13G Filing — SC 13G · Nov 8, 2024
SC 13G Filing — SC 13G · Nov 7, 2024
SC 13G Filing — SC 13G · Oct 21, 2024
QIAGEN Finalizes Convertible Bond Offering Terms — 6-K · Sep 4, 2024 Risk: medium
On September 3, 2024, QIAGEN N.V. announced the final terms for its offering of new senior, unsecured net share settled convertible bonds. The company is offeri
QIAGEN Proposes $450M Convertible Bond Offering — 6-K · Sep 3, 2024 Risk: medium
On September 3, 2024, QIAGEN N.V. announced a proposed offering of US$450.0 million in senior, unsecured net share settled convertible bonds. This offering is b
QIAGEN N.V. Files 6-K on Annual Shareholder Meeting — 6-K · Aug 2, 2024 Risk: low
QIAGEN N.V. filed a Form 6-K on August 2, 2024, reporting on its Annual General Meeting of Shareholders held on June 21, 2024. The filing includes related mater
QIAGEN N.V. Holds Capital Markets Day — 6-K · Jun 24, 2024 Risk: low
QIAGEN N.V. held a Capital Markets Day event in New York, New York on June 17, 2024. The company furnished a press release and presentation materials related to
QIAGEN Discontinues NeuMoDx Molecular Systems — 6-K · Jun 6, 2024 Risk: medium
On June 6, 2024, QIAGEN N.V. announced its decision to discontinue the NeuMoDx 96 and 288 Molecular Systems. This decision was detailed in a press release furni
QIAGEN N.V. Files Q1 2024 6-K Report — 6-K · May 1, 2024 Risk: low
QIAGEN N.V. filed a Form 6-K for the quarterly period ended March 31, 2024. The filing is a report of a foreign private issuer and includes information on other
QIAGEN N.V. Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 11, 2024 Risk:
QIAGEN N.V. (QGEN) filed a Foreign Annual Report (20-F) with the SEC on March 11, 2024. QIAGEN N.V. filed its annual report on Form 20-F for the fiscal year end
MFS Boosts QIAGEN Stake to 20.45M Shares, Signals Confidence — SC 13G/A · Feb 9, 2024 Risk: low
Massachusetts Financial Services Company (MFS) filed an amended SC 13G/A on February 9, 2024, disclosing its beneficial ownership in QIAGEN N.V. (QGEN) as of De
QIAGEN Files 6-K, Reports Unaudited Q4 & FY 2023 Results — 6-K · Feb 8, 2024 Risk: low
QIAGEN N.V. (NYSE: QGEN) filed a 6-K on February 8, 2024, to announce its unaudited financial results for the fourth quarter and full year ended December 31, 20
BlackRock Amends QIAGEN N.V. Stake, Maintains Passive Position — SC 13G/A · Jan 23, 2024
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in QIAGEN N.V. as of December 31, 2023. This amendment (Amendment No. 3)
QIAGEN Details $300M Synthetic Share Buyback Plan — 6-K · Jan 23, 2024
QIAGEN N.V. (NYSE: QGEN) announced on January 18, 2024, the details for completing a synthetic share repurchase plan of up to approximately $300 million. This p
QIAGEN to Return $300M to Shareholders via Synthetic Buyback — 6-K · Jan 8, 2024
QIAGEN N.V. (NYSE: QGEN) announced on January 7, 2024, plans to return approximately $300 million to shareholders through a synthetic share repurchase, combinin

Risk Profile

Risk Assessment: Of QGEN's 20 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Stephen H. Rusckowski

Industry Context

QIAGEN N.V. operates in the life sciences industry, focusing on molecular diagnostics and sample preparation technologies.

Top Tags

foreign-private-issuer (8) · quarterly-report (6) · sec-filing (6) · reporting (3) · capital-return (3) · earnings (2) · share-repurchase (2) · shareholder-return (2) · debt-offering (2) · convertible-bonds (2)

Key Numbers

Commission File Number: 001-38332 — Identifies the specific SEC filing for QIAGEN N.V.
Preliminary Results: Q1 2025 — Company announced preliminary results for this period.
Adjusted EPS Outlook: Full-year 2025 — Company raised its outlook for this period.
Fiscal Year: 2024 — The period covered by the 20-F filing.
Fiscal Year End: 1231 — Indicates the end of the reporting period.
Shareholder Return: $300 million — Amount QIAGEN plans to return to shareholders through a synthetic share repurchase.
Convertible Bond Offering: US$450.0 million — Principal amount of the proposed debt issuance
Filing Date: 2024-03-11 — Date the 20-F was submitted
Report Year: 2023 — The year for which the report is filed
Shares with Sole Voting Power: 20,451,464 — Represents the number of QIAGEN N.V. shares Massachusetts Financial Services Company can vote.

Forward-Looking Statements

{"claim":"Massachusetts Financial Services Company will maintain a significant stake in QIAGEN N.V. for the foreseeable future.","entity":"Massachusetts Financial Services Company","targetDate":"December 29, 2024","confidence":"high"}

Related Companies

QIAGEN · QIA

Frequently Asked Questions

What are the latest SEC filings for Qiagen N.V. (QGEN)?

Qiagen N.V. has 29 recent SEC filings from Jan 2024 to Dec 2025, including 22 6-K, 3 SC 13G, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of QGEN filings?

Across 29 filings, the sentiment breakdown is: 5 bullish, 24 neutral. The dominant sentiment is neutral.

Where can I find Qiagen N.V. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Qiagen N.V. (QGEN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Qiagen N.V.?

Financial highlights for Qiagen N.V. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for QGEN?

The investment thesis for QGEN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Qiagen N.V.?

Key executives identified across Qiagen N.V.'s filings include Stephen H. Rusckowski.

What are the main risk factors for Qiagen N.V. stock?

Of QGEN's 20 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 17 low-risk.

What are recent predictions and forward guidance from Qiagen N.V.?

Recent forward-looking statements from Qiagen N.V. include guidance on {"claim":"Massachusetts Financial Services Company will maintain a significant stake in QIAGEN N.V. for the foreseeable .